It would also raise serious questions about excessive government spending and wealth redistribution beyond reasonable programs for the benefit of the general public.
Just three months before its planned split into two companies, Abbott Laboratories is suffering a significant setback after a Phase III trial for a chronic kidney disease treatment was ended due to an excessive number of deaths and serious adverse events in patients.